Kanvas Bio has annouced the closing of $48M series A led by DCVC with participation of Gates Foundation

We are excited to share that Kanvas Biosciences, a portfolio company of Boutique Venture Partners, has announced the closing of a $48M Series A financing. The round was led by Jason Pontin of DCVC and Lions Capital, with significant participation from the Gates Foundation, among others, including Zeon Ventures Inc.Kanvas is building a leading Spatial Biology + AI drug-discovery platform focused on advancing next-generation microbiome therapeutics. The financing will support the advancement of KAN-001 into clinical trials for patients who do not fully respond to immune checkpoint inhibitors, while also accelerating the company’s spatial imaging and manufacturing platform for next-generation live biotherapeutics.Big congratulations to Matthew Cheng, Hao S., Lee Swem, Aditya Bhalla, Prof. Iwijn De Vlaminck, and the entire exceptional Kanvas team as they continue pushing the frontier of microbiome medicine forward.We are also thrilled to welcome Stephen Quake, D.Phil. of Stanford University to the Board of Directors.